FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/New Study Evaluates Peptide Therapies for Liver Disease Prevention
返回研究图书馆

New Study Evaluates Peptide Therapies for Liver Disease Prevention

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

New Study Evaluates Peptide Therapies for Liver Disease Prevention

A groundbreaking Phase 3 study has been launched to assess whether the peptide therapies tirzepatide and retatrutide can prevent major adverse liver outcomes (MALO) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This research, titled SYNERGY-Outcomes, is sponsored by Eli Lilly and Company and aims to provide valuable insights into the potential benefits of these peptide treatments.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), is a growing health concern affecting millions around the world. The condition is characterized by an accumulation of fat in the liver and can lead to inflammation, fibrosis, cirrhosis, and even liver cancer if left untreated.

Peptide therapies like tirzepatide and retatrutide have shown promise in managing metabolic disorders such as type 2 diabetes and obesity. These peptides work by targeting specific receptors in the body to regulate metabolism and appetite control. The SYNERGY-Outcomes study seeks to determine whether these peptides can also protect against severe liver complications associated with MASLD.

Key Details

The SYNERGY-Outcomes trial is currently recruiting adults who are at high risk of developing major adverse liver outcomes due to metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will be randomly assigned within a Master Protocol to receive either retatrutide, tirzepatide, or a placebo. The primary goal is to assess whether these peptide therapies can prevent serious liver complications in patients with MASLD.

The study, which is being conducted across multiple sites and sponsored by Eli Lilly and Company, will employ non-invasive tests (NITs) to identify eligible participants who are at high risk of developing MALO. This approach allows for a more precise identification of individuals most likely to benefit from the intervention.

Key Takeaways

  • Assessing Peptide Efficacy: The SYNERGY-Outcomes study aims to evaluate whether tirzepatide and retatrutide can prevent major adverse liver outcomes in patients with MASLD.
  • Non-Invasive Testing: Eligibility for the trial is determined using non-invasive tests, ensuring that participants are at high risk of developing serious liver complications.
  • Master Protocol Design: The study employs a Master Protocol design to efficiently test multiple agents within a single clinical trial framework.
  • Long-Term Impact: Results from this research could significantly impact future treatment guidelines and peptide therapy options for managing MASLD.

What This Means

For the peptide community, the SYNERGY-Outcomes study represents an important step forward in understanding the potential of peptide therapies beyond metabolic disorders. If successful, these findings may lead to new FDA-approved treatments that can protect against severe liver conditions associated with MASLD. Such advancements would not only improve patient outcomes but also further establish peptide therapy as a versatile and effective treatment modality.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。